Schedule of Investments (unaudited) December 31, 2020 | iShares® U.S. Medical Devices ETF (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks | ||||||||
Health Care Equipment — 84.1% | ||||||||
Abbott Laboratories | 11,045,738 | $ | 1,209,397,854 | |||||
ABIOMED Inc.(a)(b) | 318,934 | 103,398,402 | ||||||
AngioDynamics Inc.(a)(b) | 268,372 | 4,114,143 | ||||||
AtriCure Inc.(a)(b) | 318,145 | 17,711,132 | ||||||
Axogen Inc.(a)(b) | 246,575 | 4,413,692 | ||||||
Axonics Modulation Technologies Inc.(a)(b) | 206,661 | 10,316,517 | ||||||
Baxter International Inc. | 3,605,035 | 289,268,008 | ||||||
Becton Dickinson and Co. | 1,658,974 | 415,108,474 | ||||||
Boston Scientific Corp.(a) | 10,098,584 | 363,044,095 | ||||||
Cantel Medical Corp. | 266,247 | 20,996,238 | ||||||
Cardiovascular Systems Inc.(a)(b) | 283,166 | 12,391,344 | ||||||
CONMED Corp. | 202,112 | 22,636,544 | ||||||
CryoLife Inc.(a)(b) | 274,196 | 6,473,768 | ||||||
CryoPort Inc.(a)(b) | 276,459 | 12,131,021 | ||||||
Danaher Corp. | 3,233,423 | 718,272,585 | ||||||
DexCom Inc.(a)(b) | 677,734 | 250,571,814 | ||||||
Edwards Lifesciences Corp.(a) | 4,398,703 | 401,293,675 | ||||||
Envista Holdings Corp.(a)(b) | 1,126,713 | 38,004,029 | ||||||
GenMark Diagnostics Inc.(a)(b) | 477,304 | 6,968,638 | ||||||
Glaukos Corp.(a)(b) | 317,226 | 23,874,429 | ||||||
Globus Medical Inc., Class A(a)(b) | 538,062 | 35,092,404 | ||||||
Heska Corp.(a)(b) | 62,755 | 9,140,266 | ||||||
Hill-Rom Holdings Inc. | 471,772 | 46,219,503 | ||||||
Hologic Inc.(a) | 1,814,031 | 132,115,878 | ||||||
IDEXX Laboratories Inc.(a)(b) | 602,019 | 300,931,238 | ||||||
Inari Medical Inc.(a)(b) | 58,210 | 5,081,151 | ||||||
Inogen Inc.(a)(b) | 130,282 | 5,821,000 | ||||||
Insulet Corp.(a)(b) | 465,431 | 118,978,127 | ||||||
Integer Holdings Corp.(a)(b) | 232,496 | 18,876,350 | ||||||
Integra LifeSciences Holdings Corp.(a)(b) | 499,624 | 32,435,590 | ||||||
Intersect ENT Inc.(a) | 229,273 | 5,250,352 | ||||||
Intuitive Surgical Inc.(a)(b) | 528,414 | 432,295,493 | ||||||
iRhythm Technologies Inc.(a)(b) | 203,390 | 48,246,142 | ||||||
LeMaitre Vascular Inc. | 120,236 | 4,869,558 | ||||||
LivaNova PLC(a)(b) | 342,991 | 22,709,434 | ||||||
Masimo Corp.(a)(b) | 357,477 | 95,939,677 | ||||||
Medtronic PLC | 8,388,665 | 982,648,218 | ||||||
Mesa Laboratories Inc.(b) | 34,271 | 9,823,439 | ||||||
Natus Medical Inc.(a) | 240,670 | 4,823,027 | ||||||
Nevro Corp.(a)(b) | 242,992 | 42,061,915 | ||||||
Novocure Ltd.(a)(b) | 596,298 | 103,183,406 | ||||||
NuVasive Inc.(a)(b) | 361,960 | 20,389,207 | ||||||
Orthofix Medical Inc.(a) | 136,685 | 5,874,721 | ||||||
Penumbra Inc.(a)(b) | 237,854 | 41,624,450 | ||||||
ResMed Inc. | 1,022,782 | 217,402,542 | ||||||
Shockwave Medical Inc.(a)(b) | 219,589 | 22,775,771 | ||||||
STERIS PLC | 602,189 | 114,138,903 |
Security | Shares | Value | ||||||
| ||||||||
Health Care Equipment (continued) | ||||||||
Stryker Corp. | 1,688,790 | $ | 413,821,102 | |||||
Surmodics Inc.(a)(b) | 96,893 | 4,216,783 | ||||||
Tactile Systems Technology Inc.(a)(b) | 136,936 | 6,153,904 | ||||||
Tandem Diabetes Care Inc.(a)(b) | 438,898 | 41,993,761 | ||||||
Teleflex Inc.(b) | 328,662 | 135,267,419 | ||||||
Vapotherm Inc.(a)(b) | 151,587 | 4,071,627 | ||||||
Varex Imaging Corp.(a)(b) | 278,382 | 4,643,412 | ||||||
Varian Medical Systems Inc.(a) | 644,758 | 112,839,098 | ||||||
Zimmer Biomet Holdings Inc. | 1,462,924 | 225,421,959 | ||||||
|
| |||||||
7,757,563,229 | ||||||||
Health Care Services — 0.2% | ||||||||
BioTelemetry Inc.(a)(b) | 242,869 | 17,505,997 | ||||||
|
| |||||||
Health Care Supplies — 0.3% | ||||||||
STAAR Surgical Co.(a) | 325,071 | 25,752,125 | ||||||
|
| |||||||
Life Sciences Tools & Services — 15.2% |
| |||||||
Bio-Rad Laboratories Inc., Class A(a) | 151,910 | 88,554,416 | ||||||
Bruker Corp. | 724,008 | 39,190,553 | ||||||
NanoString Technologies Inc.(a)(b) | 310,943 | 20,795,868 | ||||||
Thermo Fisher Scientific Inc. | 2,470,026 | 1,150,488,710 | ||||||
Waters Corp.(a) | 437,915 | 108,348,929 | ||||||
|
| |||||||
1,407,378,476 | ||||||||
|
| |||||||
Total Common Stocks — 99.8% |
| 9,208,199,827 | ||||||
|
| |||||||
Short-Term Investments | ||||||||
Money Market Funds — 1.8% | ||||||||
BlackRock Cash Funds: Institutional, SL Agency Shares, 0.18%(c)(d)(e) | 153,630,039 | 153,722,217 | ||||||
BlackRock Cash Funds: Treasury, SL Agency Shares, 0.00%(c)(d) | 10,980,000 | 10,980,000 | ||||||
|
| |||||||
164,702,217 | ||||||||
|
| |||||||
Total Short -Term Investments — 1.8% |
| 164,702,217 | ||||||
|
| |||||||
Total Investments in Securities — 101.6% |
| 9,372,902,044 | ||||||
Other Assets, Less Liabilities — (1.6)% |
| (147,120,146 | ) | |||||
|
| |||||||
Net Assets — 100.0% |
| $ | 9,225,781,898 | |||||
|
|
(a) | Non-income producing security. |
(b) | All or a portion of this security is on loan. |
(c) | Affiliate of the Fund. |
(d) | Annualized 7-day yield as of period-end. |
(e) | All or a portion of this security was purchased with cash collateral received from loaned securities. |
1
Schedule of Investments (unaudited) (continued) December 31, 2020 | iShares® U.S. Medical Devices ETF |
Affiliates
Investments in issuers considered to be affiliate(s) of the Fund during the period ended December 31, 2020 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 03/31/20 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 12/31/20 | Shares Held at 12/31/20 | Income | Capital Gain Distributions from Underlying Funds |
| ||||||||||||||||||||||||||||||||
BlackRock Cash Funds: Institutional, SL Agency Shares | $ | 168,274,046 | $ | — | $ | (14,771,263 | )(a) | $ | 138,252 | $ | 81,182 | $ | 153,722,217 | 153,630,039 | $ | 715,642 | (b) | $ | — | |||||||||||||||||||||||
BlackRock Cash Funds: Treasury, SL Agency Shares | 9,823,000 | 1,157,000 | (a) | — | — | — | 10,980,000 | 10,980,000 | 12,440 | — | ||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||||||||
$ | 138,252 | $ | 81,182 | $ | 164,702,217 | $ | 728,082 | $ | — | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | Represents net amount purchased (sold). |
(b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Futures Contracts
Description | Number of Contracts | Expiration Date | Notional Amount (000) | Value/ Unrealized Appreciation (Depreciation) | ||||||||||||
Long Contracts | ||||||||||||||||
S&P Select Sector Health Care E-Mini Index | 110 | 03/19/21 | $ | 12,607 | $ | 243,589 | ||||||||||
S&P Select Sector Technology E-Mini Index | 22 | 03/19/21 | 2,884 | 122,830 | ||||||||||||
|
| |||||||||||||||
$ | 366,419 | |||||||||||||||
|
|
Fair Value Measurements
Various inputs are used in determining the fair value of financial instruments. For description of the input levels and information about the Fund’s policy regarding valuation of financial instruments, refer to a recently published shareholder report. Shareholder reports are available on the Fund’s website at iShares.com and on the U.S. Securities and Exchange Commission website at sec.gov.
The following table summarizes the value of the Fund’s investments according to the fair value hierarchy as of December 31, 2020. The breakdown of the Fund’s investments into major categories is disclosed in the Schedule of Investments above.
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Investments | ||||||||||||||||
Assets | ||||||||||||||||
Common Stocks | $ | 9,208,199,827 | $ | — | $ | — | $ | 9,208,199,827 | ||||||||
Money Market Funds | 164,702,217 | — | — | 164,702,217 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 9,372,902,044 | $ | — | $ | — | $ | 9,372,902,044 | |||||||||
|
|
|
|
|
|
|
| |||||||||
Derivative financial instruments(a) | ||||||||||||||||
Assets | ||||||||||||||||
Futures Contracts | $ | 366,419 | $ | — | $ | — | $ | 366,419 | ||||||||
|
|
|
|
|
|
|
|
(a) | Shown at the unrealized appreciation (depreciation) on the contracts. |
2